[Featured Stock] L&K Bio Secures First US Patent for Spinal Expandable Cage... Targeting World's Largest Market Upward

[Asia Economy Reporter Jang Hyowon] L&K Bio is showing strong performance. This is interpreted as the news that the company has obtained a patent for spinal implant-related technology for the first time in the world's largest market, the United States, gaining attention.

As of 11:15 AM on the 5th, L&K Bio is trading at 11,950 KRW, up 1.7% compared to the previous day.

On this day, L&K Biomed recently acquired a foundational patent in the United States for a height-expandable intervertebral body fusion device. The company had previously obtained a Korean patent in 2020 for a "height-adjustable spinal fusion cage," but this is the first time it has secured a patent related to an expandable product in the U.S.

The U.S. market is the largest spinal implant market worldwide. The core technology patents for height-expandable cages are dominated by a very small number of companies, including Globus Medical, making it the biggest barrier in the U.S. market.

This patent acquisition is evaluated as proof that L&K Biomed possesses excellent technology and high competitiveness, enough to challenge Globus, the global number one spinal implant company. Globus currently has a market capitalization of approximately 7.9 trillion KRW on the New York Stock Exchange.

This content was produced with the assistance of AI translation services.